Core Insights - Premier Health of America Inc. has reported its unaudited financial results for the third quarter ended June 30, 2025, showing a decline in revenues and an increase in net loss compared to the same period in 2024 [1][2][10] Financial Performance - Revenues for Q3 2025 were CAD 21.91 million, down from CAD 41.48 million in Q3 2024, representing a decrease of approximately 47% [2] - Gross margin for Q3 2025 was CAD 3.49 million, with a gross margin percentage of 15.9%, slightly up from 15.4% in Q3 2024 [2] - Adjusted EBITDA for Q3 2025 was CAD 22, a significant drop from CAD 367K in Q3 2024 [2][10] - The net loss for Q3 2025 was CAD 3.53 million, an improvement from a net loss of CAD 8.45 million in Q3 2024 [2][10] Operational Challenges - The implementation of Quebec's Bill 10 has negatively impacted the Per Diem segment, which now accounts for about 4% of revenues [3] - The travel nurse and northern communities' services are performing well overall, except for a decline in British Columbia due to centralization efforts by health authorities [4] - The company is reorganizing its Quebec operations, including workforce reductions, to align with cost-saving initiatives disclosed in Q4 2024 [5][6] Strategic Focus - The company is shifting its focus from the Per Diem segment to Travel Nurses and is exploring opportunities in the Home Care sector [6] - Ongoing efforts are being made to enhance cost reduction, debt management, and operational efficiency while pursuing organic growth opportunities [6]

AI and back-office software driving growth; China biopharma licensing on track for record year SAN FRANCISCO, July 29, 2025 /PRNewswire/ -- Despite a decline in overall fundraising, which is on track for the lowest amount closed in more than a decade, AI-related deal activity remains a bright spot for the healthcare sector, according to the latest report from Silicon Valley Bank (SVB), a division of First Citizens Bank. Over the last three years, all healthcare sectors saw strong growth in AI deal activity ...

Core Insights - HealthLynked Corp. has appointed Andrew Mavliev as the new Chief Technology and Product Officer, bringing over 15 years of experience in technology strategy and product development [1][4] - The company is focused on revolutionizing healthcare delivery through an integrated digital ecosystem that enhances patient engagement and connectivity [2][3] Company Overview - HealthLynked is creating an AI-powered healthcare experience that eliminates barriers between patients and providers, utilizing its proprietary ARi virtual assistant and telehealth platform [2][6] - The company's cloud-based platform connects patients with providers for both virtual and in-office appointments, consolidating medical records into a secure location [6] Leadership and Strategy - Mavliev's appointment is strategic as HealthLynked accelerates its direct-to-consumer healthtech innovations and expands its partner network [3][5] - His background includes leading the development of a super app platform that serves millions, making him well-suited to drive HealthLynked's mission [4][5] Vision and Goals - HealthLynked aims to enhance healthcare accessibility and efficiency through technology, with a focus on personalized care management and AI-driven recommendations [5][6] - Mavliev expressed excitement about applying direct-to-consumer strategies to address healthcare challenges and transform patient experiences [5]

Core Viewpoint - Premier Health of America Inc. has initiated a formal strategic review process to explore various strategic alternatives aimed at enhancing shareholder value [1][2]. Group 1: Strategic Review Process - The Board of Directors has engaged Leede Financial Inc. as a financial advisor to assist in the strategic review [2]. - No definitive timetable has been set for the completion of the review, and no decisions regarding potential strategic alternatives have been made at this time [2]. - The company does not plan to disclose further developments unless deemed appropriate or necessary [2]. Group 2: Management Focus and Incentives - While the review is ongoing, the management team is committed to delivering organic growth and maintaining service continuity across Canada [3]. - A targeted retention and incentive framework for key executives has been approved to ensure operational continuity and align management objectives with shareholder value creation during the review process [3]. Group 3: Company Overview - Premier Health is a leading Canadian health tech company that offers a comprehensive range of outsourced healthcare services to governments, corporations, and individuals [4]. - The company utilizes its proprietary LiPHe platform to drive digital transformation in the healthcare services sector, aiming to provide faster, cheaper, and more accessible care [4].

Core Viewpoint - Premier Health of America Inc. reported a significant decline in revenues and increased net loss for the second quarter ended March 31, 2025, primarily due to the impact of Quebec's Bill 10 and operational challenges in British Columbia [1][4][10]. Financial Performance - Revenues for Q2 2025 were CAD 27.1 million, down from CAD 46.3 million in Q2 2024, representing a decrease of approximately 41.4% [3]. - Gross margin for Q2 2025 was CAD 4.5 million, compared to CAD 8.5 million in Q2 2024, with gross margin as a percentage of revenues decreasing from 18.4% to 16.7% [3]. - Adjusted EBITDA for Q2 2025 was CAD 0.5 million, down from CAD 2.6 million in the same period of 2024 [10]. - The net loss for Q2 2025 was CAD 3.1 million, compared to a loss of CAD 1.5 million in Q2 2024 [10]. Operational Challenges - The implementation of Quebec's Bill 10 has significantly impacted the Per Diem segment, which now accounts for about 4% of revenues and 5% of gross margins [4]. - The travel nurse and northern communities' services are performing well, except for a volume reduction in British Columbia due to health authorities' service acquisition centralization efforts [5]. - The company is undergoing a reorganization of its Quebec operations, including workforce reductions and termination of targeted office leases, with cost savings expected to continue in the coming quarters [6]. Strategic Focus - The company is shifting its focus from the Per Diem segment to Travel Nurses and is exploring opportunities in the Home Care sector [7]. - The CFO, Guy Daoust, has taken on the role of interim CEO, emphasizing the need for further steps to adapt to ongoing operational challenges [5][7].

Investment Rating - The report indicates a positive outlook for European healthtech, highlighting a resilient venture capital funding environment and the emergence of consumer-focused healthtech unicorns [9][11]. Core Insights - The European healthtech sector is gaining momentum, particularly among consumer-focused companies, with notable unicorns like Cera, Huma, and Flo Health achieving a combined $430 million in venture funding [9]. - The overall venture capital funding in European and UK healthcare companies reached over $12.3 billion in 2024, marking the third-highest figure on record [11]. - The report emphasizes the importance of strategic partnerships between startups and large corporates, focusing on finding the right fit and developing meaningful return on investment metrics [8]. Summary by Sections Key Takeaways - Efficiency is a central theme, with companies aiming to achieve more with less, while large funding rounds may lead to inefficiencies [8]. - There is optimism regarding the potential for European companies to challenge US dominance in healthtech and life sciences, especially in light of shifting US trade policies [11]. Momentum for European Healthtech - The European venture ecosystem is forming the foundation for the next generation of consumer healthtech companies, contrasting with the US market's focus on B2B2C models [10]. - Notable funding rounds include Oura's $200 million round, elevating its valuation to $5.2 billion [9]. Spotlight on Women's Health - The report highlights the growing focus on women's health within the healthtech sector, although specific details are not provided in the extracted content. Appendix - The appendix includes a list of medtech startups showcased at the LSX World Congress, detailing their funding, valuations, and active investors [12][13].

MONTRÉAL, May 01, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announces that all matters submitted to shareholders for approval were approved at its annual general meeting of shareholders held on April 30, 2025. All matters submitted to shareholders for approval as set out in detail in the Corporation’s management Information Circular dated April 4, 2025, were approved at its annual general meeting of sha ...

MONTRÉAL, March 27, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces that Martin Legault has resigned from his role as President and Chief Executive Officer of the Corporation, as well as from his position on the Board of Directors, effective as of March 27, 2025. The Corporation thanks Mr. Legault for his 22 years of service and leadership. Guy Daoust, the Chief Financial Officer of the Corporation, has been appointed ...